858 Therapeutics Secures $50M in Series B Round for Innovations
858 Therapeutics Raises $50 Million in Series B Financing
In a significant stride towards advancing its ongoing projects, 858 Therapeutics has successfully secured $50 million in a Series B financing round. This financing, led by Avidity Partners, attracted notable participants such as Insight Partners, Mirae Asset Capital, and Alexandria Venture Investments, along with existing supporters like Versant Ventures, NEA, and Logos Capital.
Strategic Leadership Addition
This financing round also marks the inclusion of Monal Mehta, Ph.D., Managing Director at Avidity Partners, to the company’s Board of Directors, promising to enhance 858 Therapeutics’ strategic direction as it progresses in the biotech landscape.
Advancing Pipeline Initiatives
CEO Jeffrey Stafford, Ph.D., expressed pride in the robust backing from such a distinguished group of life science investors. “The Series B financing stands as a testament to our team’s commitment and the noteworthy advancements we have made in our portfolio, particularly with our PARG inhibitor ETX-19477 now in clinical evaluation,” he stated.
Focus on ETX-19477 Development
With this new capital, 858 Therapeutics aims to propel its pipeline of small molecule therapeutics forward. At the forefront is ETX-19477, a highly selective and potent inhibitor targeting the DNA repair protein PARG. The compound is currently being studied in patients suffering from advanced solid tumors, with ongoing clinical trials expected to yield valuable insights regarding patient responsiveness to PARG inhibition.
Clinical Trials and Future Directions
The Phase 1 trial for ETX-19477 is structured as a multi-center, open-label, dose escalation, and expansion study. This trial is essential for assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETX-19477. Researchers are specifically recruiting patients with particular tumor types and genetic modifications that may increase sensitivity to the treatment.
Next Steps in Development
Upon establishing a recommended dose for further expansion, the company is poised to initiate focused Phase 2 cohorts aimed at specific tumors and biomarkers, thus honing its clinical approach.
Innovative Mechanism of Action
ETX-19477 stands out as a novel small molecule that inhibits PARG, a critical player in DNA repair processes. The inhibition of PARG is believed to trigger hyperPARylation, which can lead to the death of cancer cells undergoing significant replication stress. In various animal models, the compound exhibited impressive tumor growth inhibition, which correlates with specific genetic biomarkers relevant to treatment efficacy.
Broadening Research Horizons
Currently, 858 Therapeutics is conducting the Phase 1 study to understand better how ETX-19477 can benefit patients grappling with advanced solid tumors across multiple research sites. Continuous evaluation of clinical data will be crucial for steering future development pathways.
About 858 Therapeutics
Based in San Diego, CA, 858 Therapeutics is at the forefront of biotechnology and drug discovery, focusing on creating small molecule therapies targeting novel oncology and immunology pathways. The company aims to make significant advancements in critical areas of cancer biology, including DNA damage repair and innate immunity, utilizing extensive drug discovery expertise honed over several decades.
Conclusion and Future Prospects
In summary, 858 Therapeutics is on an upward trajectory with substantial financial backing in its recent Series B financing. As the company advances its pipeline, particularly the promising ETX-19477, stakeholders can look forward to transformative developments within the oncology landscape. The synergy between investors and the management team positions 858 Therapeutics for potential breakthroughs that may change the standard of care for cancer patients.
Frequently Asked Questions
What is the latest financing amount raised by 858 Therapeutics?
858 Therapeutics recently raised $50 million in a Series B financing round.
Who are the key investors in this financing round?
The financing was led by Avidity Partners with participation from Insight Partners, Mirae Asset Capital, Alexandria Venture Investments, and existing investors.
What is the primary focus of 858 Therapeutics?
858 Therapeutics focuses on developing small molecule therapeutics aimed at oncology and immunology targets.
What is ETX-19477?
ETX-19477 is a selective inhibitor of the DNA repair protein PARG, currently being evaluated for its potential efficacy in treating advanced solid tumors.
Where is 858 Therapeutics headquartered?
The company is headquartered in San Diego, CA, a prominent biotech hub.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Examining Super Micro's Challenges Amid Regulatory Scrutiny
- The Expanding Nitrile Gloves Market and Its Growth Potential
- Septerna Initiates Promising Clinical Trial for SEP-786
- Calian Group Partners with Microsoft for Cloud Cybersecurity Solutions
- Covalon Technologies to Showcase Innovations in Vascular Access Care
- Flow Beverage Corp. Set for Key Investor Conference Engagement
- Moving iMage Technologies Reflects on Fiscal Year 2024 Outcomes
- Marqeta Sets Date for Third Quarter Financial Results Call
- Celebrating Biotech Innovation: 2024 Endpoints 11 Winners Revealed
- Promoting Cultural Unity: Insights from a Vibrant Festival
Recent Articles
- Bot Auto Secures $20M in Funding for Autonomous Truck Development
- CarMax Reports Lower Profits Despite Increased Vehicle Sales
- AbbVie's Late-Stage Trial Success for Parkinson's Treatment
- TotalEnergies Celebrates Milestone in CO2 Storage Technology
- Is Meta's Orion a Real Challenge for Apple's Future Vision?
- Crusoe Energy Joins Forces with VAST Data for Cloud Innovation
- Orchestra BioMed CEO Boosts Stake with Significant Share Acquisitions
- Spectrum Center Enhances Fan Safety with Evolv Technology
- BlackSky Gains US Navy Research Contract for Next-Gen Satellites
- GRI Bio Advances Research in Australia for IPF Treatment
- Rubrik and Pure Storage Unite to Elevate Cyber Resilience Efforts
- Expansion of Clean Fuel Initiatives by OPAL Fuels Inc.
- Xponential Fitness Partners with ACS for Breast Cancer Month
- Taysha Gene Therapies Unveils TSHA-102 Presentation Details
- Catawba Research Celebrates a Decade of Clinical Excellence
- Exploring Praxis Precision Medicines' Efficacy in Essential Tremor
- National Payroll Institute's Urgent Call for Financial Wellness
- AtoB Collaborates with Sunoco to Enhance Fuel Savings for Fleets
- CervoMed Announces Significant Research Findings for DLB
- IES Holdings Welcomes New Board Member John Louis Fouts
- Parents Fear Financial Dependence of Kids Beyond Adulthood
- Integer Holdings Corporation Announces Q3 Earnings Call Details
- Forging New Frontiers: Celebrating 50 Years of Creative Growth
- Growing Demand in Pharmaceutical Excipients Market by 2031
- Monte Carlo Welcomes Tim Miller as Chief Revenue Officer
- Leadership Transition at Pan American Energy Corp Site
- Upcoming Investor Conferences for electroCore: What to Expect
- Vertex Energy's Bankruptcy: A Journey Through Restructuring Plans
- o9 Partners with Li Auto to Transform EV Planning Strategy
- Bishop Street Underwriters Partners with Verve Services for Growth
- NICE Actimize Celebrates 2024 Innovation Award in Risk Management
- Trump's Legal Battles: Navigating Financial Liabilities Amidst Wealth Fluctuations
- Siemens Energy Leverages InfluxDB for Enhanced Operations
- Pacira BioSciences Presents Promising Data on PCRX-201 Treatment
- NaaS Technology Inc. Expands Horizon with IM Motors Partnership
- Razor Market Growth Projection to Reach Over $18 Billion by 2032
- 1&1 Versatel Enhances Nationwide Fiber Optic Network with Adtran
- Gaxos Labs Empowers Game Developers with AI Innovations
- Insights from Hilltop Securities Survey on Public Entities
- Vivani Medical's Obesity Implant Set for Clinical Trials in Australia
- Marco Di Giacomo Enhances Remote's Global Marketing Strategy
- ERES REIT Schedules Q3 2024 Financial Results and Call
- Concentrix Earnings Report Sparks Concerns Amid Market Declines
- Fifth Third Corporation Secures $50M for Community Development
- CAPREIT Sets Schedule for Upcoming Quarterly Financial Results
- Innovative Solution for Canadian Retirees to Secure Income
- Leadership Changes at TD Bank: New Co-Heads for Growth
- Emergent BioSolutions Secures $67.4M for TEMBEXA to Combat Smallpox
- SRIVARU's PRANA 2.0 Electric Motorcycle Gains Indian Certification
- Easterly Clear Ocean Expands Revenue with Strategic Vessels Sale